USFDA Approves Glenmark’s Generic Formulation for Schizophrenia Treatment

USFDA Approves Glenmark's Generic Formulation for Schizophrenia Treatment

November 7, 2023 : Glenmark Pharmaceuticals, a leading global generics, and specialty pharmaceutical company, has received final approval from the United States Food and Drug Administration (USFDA) for its generic formulation of Chlorpromazine Hydrochloride Tablets USP, in the strengths of 10 mg, 25 mg, and 50 mg, 100 mg, and 200 mg.